The Experts below are selected from a list of 3615 Experts worldwide ranked by ideXlab platform
Myung Ho Jeong - One of the best experts on this subject based on the ideXlab platform.
-
Mechanical and physio-biological properties of peptide-Coated Stent for re-endothelialization
Biomaterials Research, 2020Co-Authors: In-ho Bae, Dae Sung Park, Myung Ho Jeong, Kyung Seob Lim, Jae Won Shim, Mun Ki Kim, Jun-kyu ParkAbstract:Background The aim of this study was to characterize the mechanical and physio-biological properties of peptide-Coated Stent (PCS) compared to commercialized drug-eluting Stents (DESs). Methods WKYMVm (Trp-Lys-Tyr-Met-Val-D-Met), a stimulating peptide for homing endothelial colony-forming cell was specially synthesized and Coated to bare metal Stent (BMS) by dopamine-derived coordinated bond. Biological effects of PCS were investigated by endothelial cell proliferation assay and pre-clinical animal study. And mechanical properties were examined by various experiment. Results The peptide was well-Coated to BMS and was maintained and delivered to 21 and 7 days in vitro and in vivo, respectively. Moreover, the proliferation of endothelial cell in PCS group was increased (approximately 36.4 ± 5.77%) in PCS group at 7 day of culture compare to BMS. Although, the radial force of PCS was moderated among study group. The flexibility of PCS was (0.49 ± 0.082 N) was greatest among study group. PCS did not show the outstanding performance in recoil and foreshortening test (3.1 ± 0.22% and 2.1 ± 0.06%, respectively), which was the reasonable result under the guide line of FDA (less than 7.0%). The nominal pressure (3.0 mm in a diameter) of PCS established by compliance analysis was 9 atm. The changing of PCS diameter by expansion was similar to other DESs, which is less than 10 atm of pressure for the nominal pressure. Conclusions These results suggest that the PCS is not inferior to commercialized DES. In addition, since the PCS was fabricated as polymer–free process, secondary coating with polymer-based immunosuppressive drugs such as –limus derivatives may possible.
-
Long-term preclinical evaluation of bioabsorbable polymer-Coated drug-eluting Stent in a porcine model
Macromolecular Research, 2017Co-Authors: Jun-kyu Park, Dae Sung Park, Myung Ho Jeong, Jae Won Shim, Young Joon HongAbstract:Bioabsorbable polymer-based drug-eluting Stents have been shown to be effective and safe in the actual practice. The objective of the present study was to evaluate a biodegradable poly-L-lactic acid (PLLA)-based sirolimus-Coated Stent in comparison with a commercial everolimus-eluting Stent with a permanent polymer in a porcine coronary restenosis model on a short-, mid-, and long-term basis. Pigs were randomized into eight groups in which the coronary arteries (36 pigs with 72 coronary arteries) had either a sirolimus-eluting Stent with PLLA (SES, n =24, follow-up after 4, 12, and 24 weeks), bare metal Stent (BMS, n =12, follow-up after 4 weeks), PLLA-Coated Stent without a drug (PCS, n =12, follow-up after 4 weeks), or commercial everolimus-eluting Stent with a permanent polymer (EES, Promus PREMIER^®, n =24, follow-up after 4, 12, and 24 weeks). Histopathological analysis was performed at 4, 12, or 24 weeks after Stenting. The surface morphology of the SES, visualized using an optical microscope and a scanning electron microscope, was smooth and uniform with virtually no defects. Sirolimus was released slowly over 60 days. There was no significant difference in the percent area stenosis between the SES and EES at any of the follow-up time points (13.0±8.10% in SES vs . 14.1±9.12% in EES at 4 weeks, 23.1±8.63% in SES vs . 21.3±7.92% in EES at 12 weeks, 28.2±8.20% in SES vs. 25.1±8.51% in EES at 24 weeks, each p =NS). The percent area stenosis using micro-computed tomography and intravenous ultrasound demonstrated similar restenosis rates with histopathological stenosis between the SES and EES. The SES with a biodegradable polymer was as effective as the commercial EES with a permanent polymer in inhibiting neointima proliferation at 4, 12, and 24 weeks in a porcine coronary restenosis model.
-
EFFECT OF NON-POLYMER TITANIUM DIOXIDE THIN FILM Coated Stent WITH HEPARIN IN PORCINE CORONARY RESTENOSIS MODEL
Journal of the American College of Cardiology, 2016Co-Authors: Suyoung Jang, Kyung Seob Lim, Ji Eun Song, Myung Ho JeongAbstract:Drug-eluting Stents (DES) without polymer may overcome the defects of DES using polymer. The aim of this study was to examine the effect of the non-polymer titatanium dioxide (TiO2) thin film-Coated Stent with heparin in a porcine coronary overstretch restenosis model. Pigs were randomized into
-
thromboresistant and endothelialization effects of dopamine mediated heparin coating on a Stent material surface
Journal of Materials Science: Materials in Medicine, 2012Co-Authors: Inkyu Park, Dae Sung Park, Myung Ho JeongAbstract:Heparinization of surfaces has proven a successful strategy to prevent thrombus formation. Inspired by the composition of adhesive proteins in mussels, the authors used dopamine to immobilize heparin on a Stent surface. This study aimed to assess the thromboresistant and endothelialization effects of dopamine-mediated heparin (HPM) coating on a Stent material surface. The HPM was synthesized by bonding dopamine and heparin chemically. Cobalt–chromium (Co–Cr) alloy disks were first placed in the HPM solution and applied to surface stability then underwent thromboresistant tests and human umbilical vein endothelial cells (HUVEC) cytotoxicity assays. The results showed not only thromboresistant activity and a stable state of heparin on the surfaces after investigation with toluidine blue and thrombin activation assay but also proliferation of HUVEC in vitro. Studies on animals showed that the HPM-Coated Stent has no obvious inflammation response and increasing of restenosis rate compared to the bare metal Stent (BMS) indicating good biocompatibility as well as safety in its in vivo application. Moreover, improving the endothelial cell (EC) proliferation resulted in a higher strut-covering rate (i.e., endothelialization) with shuttle-shaped EC in the HPM-Coated Stent group compared to that of the BMS group. These results suggest that this facile coating approach could significantly promote endothelialization and offer greater safety than the BMS for its much improved thromboresistant property. Moreover, it may offer a platform for conjugating secondary drugs such as anti-proliferative drugs.
-
thromboresistant and endothelialization effects of dopamine mediated heparin coating on a Stent material surface
Journal of Materials Science: Materials in Medicine, 2012Co-Authors: Inkyu Park, Dae Sung Park, Myung Ho JeongAbstract:Heparinization of surfaces has proven a successful strategy to prevent thrombus formation. Inspired by the composition of adhesive proteins in mussels, the authors used dopamine to immobilize heparin on a Stent surface. This study aimed to assess the thromboresistant and endothelialization effects of dopamine-mediated heparin (HPM) coating on a Stent material surface. The HPM was synthesized by bonding dopamine and heparin chemically. Cobalt–chromium (Co–Cr) alloy disks were first placed in the HPM solution and applied to surface stability then underwent thromboresistant tests and human umbilical vein endothelial cells (HUVEC) cytotoxicity assays. The results showed not only thromboresistant activity and a stable state of heparin on the surfaces after investigation with toluidine blue and thrombin activation assay but also proliferation of HUVEC in vitro. Studies on animals showed that the HPM-Coated Stent has no obvious inflammation response and increasing of restenosis rate compared to the bare metal Stent (BMS) indicating good biocompatibility as well as safety in its in vivo application. Moreover, improving the endothelial cell (EC) proliferation resulted in a higher strut-covering rate (i.e., endothelialization) with shuttle-shaped EC in the HPM-Coated Stent group compared to that of the BMS group. These results suggest that this facile coating approach could significantly promote endothelialization and offer greater safety than the BMS for its much improved thromboresistant property. Moreover, it may offer a platform for conjugating secondary drugs such as anti-proliferative drugs.
Renu Virmani - One of the best experts on this subject based on the ideXlab platform.
-
tct 410 assessing suitability for short term dapt thromboresistance albumin retention and endothelial function in the resolute onyx zotarolimus versus biofreedom biolimus eluting coronary Stent systems
Journal of the American College of Cardiology, 2019Co-Authors: Hiroyuki Jinnouchi, Frank D Kolodgie, Qi Cheng, Anne Cornelissen, Christine Janifer, Atsushi Sakamoto, Yu Sato, Liang Guo, Stefan Tunev, Renu VirmaniAbstract:Thromboresistance and endothelial function have never been compared between current best-in-generation Resolute Onyx Zotarolimus-Eluting Coronary Stent System (RO-DES) and the BioFreedom polymer-free drug-Coated Stent (BF-DCS). In an ex vivo carotid to pig arteriovenous shunt model,
-
Polymer-Free Biolimus A9-Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model
Circulation-cardiovascular Interventions, 2010Co-Authors: Norio Tada, Lauren Bartlett, Alexander Black, Claudia F. Clavijo, Ron Betts, Doug Savage, Gordon Grant, Uwe Christians, Renu Virmani, Shih-horng SuAbstract:Background— Drug-eluting Stents effectively reduce restenosis but may increase late thrombosis and delayed restenosis. PersiStent polymer, the drug, or a combination of both could be responsible. Local delivery of Biolimus A9, a rapamycin derivative, from a polymer-free BioFreedom Stent (Biosensors International) may prevent these complications. Methods and Results— We compared high-dose (HD) (225 μg/14 mm Biolimus A9) and low-dose (LD) (112 μg/14 mm Biolimus A9) BioFreedom Stents with a polymer-Coated sirolimus-eluting Cypher Stent (SES) and a bare-metal Stent (BMS) at 28 days and 180 days in an overstretch coronary mini-swine model with histomorphometric and histological analysis. At 28 days, there was a reduction in neointimal proliferation by HD, LD, and SES compared with BMS (neointimal thickness: HD, 0.080±0.032; LD, 0.085±0.038; SES, 0.064±0.037; BMS, 0.19±0.111 mm; P HD/LD/SES). At 180 days, both BioFreedom Stents were associated with reduced neointimal proliferation, whereas SES exhibited increased neointima (neointimal thickness: HD, 0.12±0.034; LD, 0.10±0.040; SES, 0.20±0.111; BMS, 0.17±0.099 mm; P HD/LD; BMS > LD). At 180 days, BioFreedom Stents showed decreased fibrin and inflammation, including granuloma and giant cells, compared with SES. Conclusions— The polymer-free Biolimus A9-Coated Stent demonstrates equivalent early and superior late reduction of intimal proliferation compared with SES in a porcine model. After implantation of BioFreedom Stent, delayed arterial healing was minimal, and there was no increased inflammation at 180 days compared with SES implantation. The use of polymer-free Stents may have a potential long-term benefit over traditional polymeric-Coated drug-eluting Stents. Received May 4, 2009; accepted February 22, 2010. # CLINICAL PERSPECTIVE {#article-title-2}
-
pathological analysis of local delivery of paclitaxel via a polymer Coated Stent
Circulation, 2001Co-Authors: Andrew Farb, Frank D Kolodgie, Phillip F Heller, Sweta Shroff, Linda Cheng, Andrew J Carter, Douglas S Scott, Jeffrey P Froehlich, Renu VirmaniAbstract:Background— Paclitaxel can inhibit vascular smooth muscle proliferation in vitro, and early studies suggest that paclitaxel may be useful in preventing restenosis. Early and late intimal growth and local vascular pathological changes associated with paclitaxel delivered via Stents have not been fully explored. Methods and Results— Localized drug delivery was accomplished with balloon-expandable stainless steel Stents Coated with a cross-linked biodegradable polymer, chondroitin sulfate and gelatin (CSG), containing various doses of paclitaxel. CSG-Coated Stents with paclitaxel (42.0, 20.2, 8.6, or 1.5 μg of paclitaxel per Stent), CSG-Coated Stents without paclitaxel, and unCoated Stents (without paclitaxel or CSG) were deployed in the iliac arteries of New Zealand White rabbits, which were killed 28 days after implant. Mean neointimal thickness at Stent strut sites was reduced 49% (P<0.0003) and 36% (P<0.007) with Stents containing 42.0 and 20.2 μg of paclitaxel per Stent, respectively, versus CSG-Coated ...
-
Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent
Circulation, 2001Co-Authors: Andrew Farb, Frank D Kolodgie, Phillip F Heller, Sweta Shroff, Linda Cheng, Andrew J Carter, Douglas S Scott, Jeffrey P Froehlich, Renu VirmaniAbstract:Background— Paclitaxel can inhibit vascular smooth muscle proliferation in vitro, and early studies suggest that paclitaxel may be useful in preventing restenosis. Early and late intimal growth and local vascular pathological changes associated with paclitaxel delivered via Stents have not been fully explored. Methods and Results— Localized drug delivery was accomplished with balloon-expandable stainless steel Stents Coated with a cross-linked biodegradable polymer, chondroitin sulfate and gelatin (CSG), containing various doses of paclitaxel. CSG-Coated Stents with paclitaxel (42.0, 20.2, 8.6, or 1.5 μg of paclitaxel per Stent), CSG-Coated Stents without paclitaxel, and unCoated Stents (without paclitaxel or CSG) were deployed in the iliac arteries of New Zealand White rabbits, which were killed 28 days after implant. Mean neointimal thickness at Stent strut sites was reduced 49% (P
Pavlos Toutouzas - One of the best experts on this subject based on the ideXlab platform.
-
Stents wrapped in autologous vein: an experimental study.
Journal of the American College of Cardiology, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Panayiotis Karayannakos, Pavlos Toutouzas, Michael M. Gravanis, Keith A. RobinsonAbstract:Abstract Objectives. A new type of Coated Stent, consisting of a conventional Stent covered by an autologous vein graft, was developed at our institution. Background. Coated Stents are under investigation to address Stenting limitations. However, experimental implantation of Coated Stents covered by autologous tissue has not been reported. Methods. An autologous vein graft was removed and carefully prepared. Subsequently, a Palmaz Stent was covered by the vein graft both internally and externally. Twenty-seven Stents were implanted in the normal iliac arteries of 27 pigs weighing 18 to 33 kg. In 15 of the pigs, 15 nonCoated Palmaz Stents were implanted in the contralateral artery; these animals served as the control group. The animals were followed up angiographically for a period ranging from 7 days to 6 months. At the time of death, the Stented segments were removed, and histomorphometric analysis was performed. Results. Autologous vein graft-Coated Stent preparation and implantation was feasible and uncomplicated. In both Stents, angiographic follow-up revealed the absence of thrombosis, except for two cases of subacute thrombosis in the control group. The thickness of the intimal layer was greater in the Coated Stents and seems to be due to the existence of the internal vein layer ([mean ± SD] 0.57 ± 0.12 vs. 0.27 ± 0.13 mm, p = 0.001). The arterial media of the Coated Stent segments was thinner than that in the control group (0.14 ± 0.03 vs. 0.18 ± 0.01 mm, p = 0.02). Conclusions. The autologous vein graft-Coated Stent seems to be nonthrombogenic, and only minimal hyperplasia was observed in the pigs. Further studies are needed to explore the efficacy of this technique in humans.
-
Autologous vein graft-Coated Stent for treatment of coronary artery disease.
Catheterization and cardiovascular diagnosis, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Acute or subacute thrombosis and late restenosis remain the main limitations of permanent Stenting. In an effort to address these limitations, an autologous vein graft-Coated Stent (AVGCS) was developed at our institution. This Stent consists of a conventional Stent (Palmaz or Palmaz-Schatz, Johnson and Johnson), which is covered by an autologous vein graft. After successful experimental implantation, we report here the immediate results of the percutaneous implantation of AVGCS in 7 patients with coronary artery disease (6 de novo lesions and 1 bailout case). The results of this preliminary study indicate that the preparation of the AVGCS is easy and feasible. The implantation of the AVGCS was uncomplicated, and the immediate angiographic results were excellent. This new type of Coated Stent may be useful in addressing current limitations of balloon angioplasty.
Bodo Cremers - One of the best experts on this subject based on the ideXlab platform.
-
Inhibition of neointimal hyperplasia with a novel zotarolimus Coated balloon catheter
Clinical Research in Cardiology, 2012Co-Authors: Bodo Cremers, John L. Toner, Lewis B. Schwartz, Ulrich Speck, Nicola Kaufels, Yvonne P. Clever, Dirk Mahnkopf, Michael Böhm, Randolf Oepen, Bruno SchellerAbstract:Background Non Stent based delivery of antiproliferative agents using drug Coated balloon catheters may offer additional flexibility and efficacy in a broad range of applications. The lipophilic antiproliferative drug zotarolimus makes it a potential candidate for balloon delivery. The aim of the present study was to evaluate the safety and efficacy of a prototype zotarolimus Coated balloon (ZCB) catheter in comparison to a zotarolimus eluting Stent (ZES) in the porcine coronary overstretch model. Methods Eighty-four Stents (diameters 3.0 and 3.5 mm; length 15 mm) were implanted in LAD and Cx of 42 domestic pigs: control (TriMaxx, Abbott, polymer Coated Stent without drug, implanted with unCoated PCI catheter, n = 56); ZES (ZoMaxx, Abbott, Stent Coated with zotarolimus in polymer, implanted with unCoated PCI catheter, n = 14); ZCB (TriMaxx, Abbott, polymer Coated Stent without drug, implanted with zotarolimus Coated PCI catheter, n = 14). Drug content of the vessel wall ( n = 9) was measured about 10–30 min post intervention with ZCB in additional pigs. Results Immediately after ZCB treatment 101 ± 31 μg of zotarolimus was detected in the coronary arteries. After 28 days ZES led to a reduction of neointimal area from 4.32 ± 1.45 to 3.32 ± 1.11 mm^2 ( P = 0.019 vs. control). The effect of neointimal inhibition was more pronounced with the novel ZCB (2.79 ± 1.43 mm², P = 0.001 vs. control). Inflammation score was significantly reduced in vessels treated with the ZCB (0.75 ± 0.86 compared to control (1.45 ± 0.94, P = 0.013) and ZES (1.65 ± 0.90, P = 0.012). Conclusion Zotarolimus Coated balloons and Stents were found to effectively reduce neointimal proliferation in the porcine coronary model. Inflammation scores were significantly reduced after treatment with the Coated balloon. Zotarolimus balloon coating might be a novel option in preventing and treating restenosis.
-
Inhibition of neointimal hyperplasia with a novel zotarolimus Coated balloon catheter
Clinical research in cardiology : official journal of the German Cardiac Society, 2012Co-Authors: Bodo Cremers, John L. Toner, Lewis B. Schwartz, Randolf Von Oepen, Ulrich Speck, Nicola Kaufels, Yvonne P. Clever, Dirk Mahnkopf, Michael Böhm, Bruno SchellerAbstract:Non Stent based delivery of antiproliferative agents using drug Coated balloon catheters may offer additional flexibility and efficacy in a broad range of applications. The lipophilic antiproliferative drug zotarolimus makes it a potential candidate for balloon delivery. The aim of the present study was to evaluate the safety and efficacy of a prototype zotarolimus Coated balloon (ZCB) catheter in comparison to a zotarolimus eluting Stent (ZES) in the porcine coronary overstretch model. Eighty-four Stents (diameters 3.0 and 3.5 mm; length 15 mm) were implanted in LAD and Cx of 42 domestic pigs: control (TriMaxx, Abbott, polymer Coated Stent without drug, implanted with unCoated PCI catheter, n = 56); ZES (ZoMaxx, Abbott, Stent Coated with zotarolimus in polymer, implanted with unCoated PCI catheter, n = 14); ZCB (TriMaxx, Abbott, polymer Coated Stent without drug, implanted with zotarolimus Coated PCI catheter, n = 14). Drug content of the vessel wall (n = 9) was measured about 10–30 min post intervention with ZCB in additional pigs. Immediately after ZCB treatment 101 ± 31 μg of zotarolimus was detected in the coronary arteries. After 28 days ZES led to a reduction of neointimal area from 4.32 ± 1.45 to 3.32 ± 1.11 mm2 (P = 0.019 vs. control). The effect of neointimal inhibition was more pronounced with the novel ZCB (2.79 ± 1.43 mm², P = 0.001 vs. control). Inflammation score was significantly reduced in vessels treated with the ZCB (0.75 ± 0.86 compared to control (1.45 ± 0.94, P = 0.013) and ZES (1.65 ± 0.90, P = 0.012). Zotarolimus Coated balloons and Stents were found to effectively reduce neointimal proliferation in the porcine coronary model. Inflammation scores were significantly reduced after treatment with the Coated balloon. Zotarolimus balloon coating might be a novel option in preventing and treating restenosis.
-
paclitaxel Coated balloon catheter versus paclitaxel Coated Stent for the treatment of coronary in Stent restenosis
Circulation, 2009Co-Authors: Martin Unverdorben, Bodo Cremers, Christian Vallbracht, Hubertus Heuer, Christian Hengstenberg, Christian Maikowski, Gerald S Werner, Diethmar Antoni, Franz X Kleber, Wolfgang BockschAbstract:Background—Treatment of in-Stent restenosis with paclitaxel-Coated balloon catheter as compared with plain balloon angioplasty has shown surprisingly low late lumen loss at 6 months and fewer major adverse cardiac events up to 2 years. We compared the efficacy and safety of a paclitaxel-Coated balloon with a paclitaxel-eluting Stent as the current standard of care. Methods and Results—One hundred thirty-one patients with coronary in-Stent restenosis were randomly assigned to treatment by a paclitaxel-Coated balloon (3 g/mm 2 ) or a paclitaxel-eluting Stent. The main inclusion criteria encompassed diameter stenosis of 70% and 22 mm in length, with a vessel diameter of 2.5 to 3.5 mm. The primary end point was angiographic in-segment late lumen loss. Quantitative coronary angiography revealed no differences in baseline parameters. At 6 months follow-up, in-segment late lumen loss was 0.380.61 mm in the drug-eluting Stent group versus 0.170.42 mm (P0.03) in the drug-Coated balloon group, resulting in a binary restenosis rate of 12 of 59 (20%) versus 4 of 57 (7%; P0.06). At 12 months, the rate of major adverse cardiac events were 22% and 9%, respectively (P0.08). This difference was primarily due to the need for target lesion revascularization in 4 patients (6%) in the Coated-balloon group, compared with 10 patients (15%) in the Stent group (P0.15). Conclusions—Treatment of coronary in-Stent restenosis with the paclitaxel-Coated balloon was at least as efficacious and as well tolerated as the paclitaxel-eluting Stent. For the treatment of in-Stent restenosis, inhibition of re-restenosis does not require a second Stent implantation. (Circulation. 2009;119:2986-2994.)
Christodoulos Stefanadis - One of the best experts on this subject based on the ideXlab platform.
-
Stents wrapped in autologous vein: an experimental study.
Journal of the American College of Cardiology, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Panayiotis Karayannakos, Pavlos Toutouzas, Michael M. Gravanis, Keith A. RobinsonAbstract:Abstract Objectives. A new type of Coated Stent, consisting of a conventional Stent covered by an autologous vein graft, was developed at our institution. Background. Coated Stents are under investigation to address Stenting limitations. However, experimental implantation of Coated Stents covered by autologous tissue has not been reported. Methods. An autologous vein graft was removed and carefully prepared. Subsequently, a Palmaz Stent was covered by the vein graft both internally and externally. Twenty-seven Stents were implanted in the normal iliac arteries of 27 pigs weighing 18 to 33 kg. In 15 of the pigs, 15 nonCoated Palmaz Stents were implanted in the contralateral artery; these animals served as the control group. The animals were followed up angiographically for a period ranging from 7 days to 6 months. At the time of death, the Stented segments were removed, and histomorphometric analysis was performed. Results. Autologous vein graft-Coated Stent preparation and implantation was feasible and uncomplicated. In both Stents, angiographic follow-up revealed the absence of thrombosis, except for two cases of subacute thrombosis in the control group. The thickness of the intimal layer was greater in the Coated Stents and seems to be due to the existence of the internal vein layer ([mean ± SD] 0.57 ± 0.12 vs. 0.27 ± 0.13 mm, p = 0.001). The arterial media of the Coated Stent segments was thinner than that in the control group (0.14 ± 0.03 vs. 0.18 ± 0.01 mm, p = 0.02). Conclusions. The autologous vein graft-Coated Stent seems to be nonthrombogenic, and only minimal hyperplasia was observed in the pigs. Further studies are needed to explore the efficacy of this technique in humans.
-
Autologous vein graft-Coated Stent for treatment of coronary artery disease.
Catheterization and cardiovascular diagnosis, 1996Co-Authors: Christodoulos Stefanadis, Konstantinos Toutouzas, Charalambos Vlachopoulos, Costas Stratos, Ioannis Kallikazaros, Eleftherios Tsiamis, Manolis Vavuranakis, Pavlos ToutouzasAbstract:Acute or subacute thrombosis and late restenosis remain the main limitations of permanent Stenting. In an effort to address these limitations, an autologous vein graft-Coated Stent (AVGCS) was developed at our institution. This Stent consists of a conventional Stent (Palmaz or Palmaz-Schatz, Johnson and Johnson), which is covered by an autologous vein graft. After successful experimental implantation, we report here the immediate results of the percutaneous implantation of AVGCS in 7 patients with coronary artery disease (6 de novo lesions and 1 bailout case). The results of this preliminary study indicate that the preparation of the AVGCS is easy and feasible. The implantation of the AVGCS was uncomplicated, and the immediate angiographic results were excellent. This new type of Coated Stent may be useful in addressing current limitations of balloon angioplasty.